Articles from Waldencast plc

Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive Transformation

Obagi Medical delivers H1 2025 double-digit growth in its Core Strategic Channels. Novaestiq Acquisition Doubles the Brand’s Addressable Market in the U.S.

By Waldencast plc · Via GlobeNewswire · August 18, 2025

Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand

Acquisition strengthens Obagi Medical’s product portfolio with proven, scientifically backed, injectable portfolio

By Waldencast plc · Via GlobeNewswire · July 23, 2025